CSL share price lifts as plasma collections continue recovery

What's boosting the CSL share price today?

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is up nearly 2% today 
  • In today's news, CSL advised plasma collections are now at pre-COVID-19 levels 
  • The company's share price has descended 5% year to date 

The CSL Ltd (ASX: CSL) share price is in the green today after the company presented at the 2022 Macquarie Australia Conference in Sydney.

CSL shares are currently swapping hands at $275.38, a 1.82% gain. In contrast, the S&P/ASX 200 Index (ASX: XJO) is 0.1% lower at the time of writing.

Let's take a look at what CSL reported today.

Why is the CSL share price lifting?

CSL informed the market that plasma collections are now at roughly the same level as prior to the COVID-19 pandemic.

In a presentation at the Macquarie conference, CSL also advised the company's gross margin is predicted to return to pre-COVID levels in the future. CSL is working on technology improvements to plasma collection, reducing donation time by 30%.

CSL reported capital expenditure (CAPEX) is expected to be about $1.2 billion in FY22.

The company also highlighted the benefits of the Vifor Pharma acquisition. CSL is expecting regulatory approvals and closure on this deal by mid-2022.

CSL conducted a $750 million share plan for the acquisition in February, receiving strong support.

The CSL share price climbed nearly 2% in April amid multiple positive broker notes. Citi has placed a $335 price target on the company's share price. This is nearly a 22% upside on the current share price.

CSL is predicting a net profit after tax (NPAT) of between $2.15 to $2.25 billion in FY22.

CSL share price snapshot

The CSL share price has climbed 1.55% in the past year but it has fallen more than 5% year to date.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 5% over the past year.

CSL has a market capitalisation of about $132.6 billion based on today's share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »